Elite in Basal Cell Skin Cancer

Alexander D. Guminski

40 Rocklands Rd, 
Wollstonecraft, NSW, AU 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Basal Cell Skin Cancer
40 Rocklands Rd, 
Wollstonecraft, NSW, AU 
OverviewLocationsClinical Research

Overview

Alexander Guminski practices in Wollstonecraft, Australia. Mr. Guminski is rated as an Elite expert by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Basal Cell Skin Cancer, Melanoma, Merkel Cell Carcinoma, and Neuroendocrine Tumor.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Basal Cell Skin Cancer.

Gender
Male

Locations

40 Rocklands Rd, Wollstonecraft, NSW 2065, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Radiation, Drug
Study Drug: Avelumab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

86 Total Publications

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
Journal: Journal of neuro-oncology
Published: September 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guminski's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile